RAF1 and non-small cell lung carcinoma: In an early study of the anti-c-raf ASO, ISIS-5132, as monotherapy, toxicity was considered acceptable, but there was no clinical benefit seen in 18 patients with non-small cell lung cancer (NSCLC) (Coudert et al., 2001).